D
Mesa Laboratories, Inc.
MLAB
$122.33
-$1.09-0.88%
D
Sell
2/19/2025Upgraded
Mesa Laboratories, Inc. (MLAB) was upgraded to D from D- on 2/19/2025 due to an increase in the volatility index and total return index.
Mesa Laboratories, Inc. (MLAB) was upgraded to D from D- on 2/19/2025 due to an increase in the volatility index and total return index.
D
Sell
1/21/2025Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to D- from D on 1/21/2025 due to a decline in the valuation index.
Mesa Laboratories, Inc. (MLAB) was downgraded to D- from D on 1/21/2025 due to a decline in the valuation index.
D
Sell
1/6/2025Upgraded
Mesa Laboratories, Inc. (MLAB) was upgraded to D from D- on 1/6/2025 due to an increase in the total return index and volatility index.
Mesa Laboratories, Inc. (MLAB) was upgraded to D from D- on 1/6/2025 due to an increase in the total return index and volatility index.
D
Sell
12/10/2024Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to D- from D on 12/10/2024 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 1.19 to 0.43.
Mesa Laboratories, Inc. (MLAB) was downgraded to D- from D on 12/10/2024 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 1.19 to 0.43.
D
Sell
11/5/2024Upgraded
Mesa Laboratories, Inc. (MLAB) was upgraded to D from D- on 11/5/2024 due to a noticeable increase in the total return index, volatility index and solvency index. Debt to equity declined from 1.55 to 1.43.
Mesa Laboratories, Inc. (MLAB) was upgraded to D from D- on 11/5/2024 due to a noticeable increase in the total return index, volatility index and solvency index. Debt to equity declined from 1.55 to 1.43.
D
Sell
7/18/2024Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to D- from D on 7/18/2024 due to a significant decline in the efficiency index, solvency index and total return index. Net income declined 12,131.33% from $2.12M to -$254.58M, debt to equity increased from 0.59 to 1.55, and total capital declined 41.74% from $646.52M to $376.69M.
Mesa Laboratories, Inc. (MLAB) was downgraded to D- from D on 7/18/2024 due to a significant decline in the efficiency index, solvency index and total return index. Net income declined 12,131.33% from $2.12M to -$254.58M, debt to equity increased from 0.59 to 1.55, and total capital declined 41.74% from $646.52M to $376.69M.
D
Sell
4/28/2022Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to D from D+ on 4/28/2022 due to a noticeable decline in the volatility index and total return index.
Mesa Laboratories, Inc. (MLAB) was downgraded to D from D+ on 4/28/2022 due to a noticeable decline in the volatility index and total return index.
D
Sell
4/18/2022Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to D+ from C- on 4/18/2022 due to a major decline in the total return index and volatility index.
Mesa Laboratories, Inc. (MLAB) was downgraded to D+ from C- on 4/18/2022 due to a major decline in the total return index and volatility index.
C
Hold
2/7/2022Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to C- from C on 2/7/2022 due to a significant decline in the growth index, total return index and solvency index. Earnings per share declined from $0.7 to -$0.3937, EBIT declined 145.39% from $4.2M to -$1.91M, and the quick ratio declined from 10.49 to 1.9.
Mesa Laboratories, Inc. (MLAB) was downgraded to C- from C on 2/7/2022 due to a significant decline in the growth index, total return index and solvency index. Earnings per share declined from $0.7 to -$0.3937, EBIT declined 145.39% from $4.2M to -$1.91M, and the quick ratio declined from 10.49 to 1.9.
C
Hold
1/3/2022Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to C from C+ on 1/3/2022 due to a noticeable decline in the total return index and valuation index.
Mesa Laboratories, Inc. (MLAB) was downgraded to C from C+ on 1/3/2022 due to a noticeable decline in the total return index and valuation index.
C
Hold
12/15/2021Upgraded
Mesa Laboratories, Inc. (MLAB) was upgraded to C+ from C on 12/15/2021 due to an increase in the total return index.
Mesa Laboratories, Inc. (MLAB) was upgraded to C+ from C on 12/15/2021 due to an increase in the total return index.
C
Hold
11/26/2021Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to C from C+ on 11/26/2021 due to a decline in the total return index.
Mesa Laboratories, Inc. (MLAB) was downgraded to C from C+ on 11/26/2021 due to a decline in the total return index.
C
Hold
11/9/2021Upgraded
Mesa Laboratories, Inc. (MLAB) was upgraded to C+ from C on 11/9/2021 due to a significant increase in the total return index and solvency index. The quick ratio increased from 8.86 to 10.49.
Mesa Laboratories, Inc. (MLAB) was upgraded to C+ from C on 11/9/2021 due to a significant increase in the total return index and solvency index. The quick ratio increased from 8.86 to 10.49.
C
Hold
6/3/2021Upgraded
Mesa Laboratories, Inc. (MLAB) was upgraded to C from C- on 6/3/2021 due to a significant increase in the growth index and efficiency index. EBIT increased 1,933.33% from $234 to $4.76M, net income increased 186.31% from -$4.54M to $3.92M, and earnings per share increased from -$0.89 to $0.7392.
Mesa Laboratories, Inc. (MLAB) was upgraded to C from C- on 6/3/2021 due to a significant increase in the growth index and efficiency index. EBIT increased 1,933.33% from $234 to $4.76M, net income increased 186.31% from -$4.54M to $3.92M, and earnings per share increased from -$0.89 to $0.7392.
C
Hold
2/23/2021Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to C- from C on 2/23/2021 due to a decline in the total return index.
Mesa Laboratories, Inc. (MLAB) was downgraded to C- from C on 2/23/2021 due to a decline in the total return index.
C
Hold
2/8/2021Upgraded
Mesa Laboratories, Inc. (MLAB) was upgraded to C from C- on 2/8/2021 due to a noticeable increase in the total return index, solvency index and volatility index. Debt to equity declined from 0.37 to 0.35.
Mesa Laboratories, Inc. (MLAB) was upgraded to C from C- on 2/8/2021 due to a noticeable increase in the total return index, solvency index and volatility index. Debt to equity declined from 0.37 to 0.35.
C
Hold
8/7/2020Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to C- from C on 8/7/2020 due to a substantial decline in the growth index, efficiency index and volatility index. Operating cash flow declined 75.39% from $8.4M to $2.07M, EBIT declined 38.84% from $4.52M to $2.76M, and total revenue declined 12.47% from $34.21M to $29.94M.
Mesa Laboratories, Inc. (MLAB) was downgraded to C- from C on 8/7/2020 due to a substantial decline in the growth index, efficiency index and volatility index. Operating cash flow declined 75.39% from $8.4M to $2.07M, EBIT declined 38.84% from $4.52M to $2.76M, and total revenue declined 12.47% from $34.21M to $29.94M.
C
Hold
6/3/2020Upgraded
Mesa Laboratories, Inc. (MLAB) was upgraded to C from C- on 6/3/2020 due to a substantial increase in the growth index. Earnings per share increased from -$1.0602 to -$0.3869, EBIT increased 39.86% from $3.23M to $4.52M, and total revenue increased 8.07% from $31.66M to $34.21M.
Mesa Laboratories, Inc. (MLAB) was upgraded to C from C- on 6/3/2020 due to a substantial increase in the growth index. Earnings per share increased from -$1.0602 to -$0.3869, EBIT increased 39.86% from $3.23M to $4.52M, and total revenue increased 8.07% from $31.66M to $34.21M.
C
Hold
5/12/2020Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to C- from C on 5/12/2020 due to a significant decline in the total return index, growth index and efficiency index. Net income declined 251.21% from $3.06M to -$4.63M, earnings per share declined from $0.71 to -$1.0602, and EBIT declined 29.56% from $4.58M to $3.23M.
Mesa Laboratories, Inc. (MLAB) was downgraded to C- from C on 5/12/2020 due to a significant decline in the total return index, growth index and efficiency index. Net income declined 251.21% from $3.06M to -$4.63M, earnings per share declined from $0.71 to -$1.0602, and EBIT declined 29.56% from $4.58M to $3.23M.
C
Hold
5/15/2019Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to C from C+ on 5/15/2019 due to a decline in the total return index and valuation index.
Mesa Laboratories, Inc. (MLAB) was downgraded to C from C+ on 5/15/2019 due to a decline in the total return index and valuation index.
C
Hold
2/5/2019Upgraded
Mesa Laboratories, Inc. (MLAB) was upgraded to C+ from C on 2/5/2019 due to a substantial increase in the total return index, growth index and efficiency index. Operating cash flow increased 175.96% from $3.66M to $10.09M, EBIT increased 12.42% from $4.44M to $4.99M, and total revenue increased 7.31% from $24.87M to $26.68M.
Mesa Laboratories, Inc. (MLAB) was upgraded to C+ from C on 2/5/2019 due to a substantial increase in the total return index, growth index and efficiency index. Operating cash flow increased 175.96% from $3.66M to $10.09M, EBIT increased 12.42% from $4.44M to $4.99M, and total revenue increased 7.31% from $24.87M to $26.68M.
C
Hold
1/10/2019Upgraded
Mesa Laboratories, Inc. (MLAB) was upgraded to C from C- on 1/10/2019 due to an increase in the total return index, volatility index and efficiency index.
Mesa Laboratories, Inc. (MLAB) was upgraded to C from C- on 1/10/2019 due to an increase in the total return index, volatility index and efficiency index.
C
Hold
11/1/2018Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to C- from C on 11/1/2018 due to a large decline in the total return index, dividend index and valuation index.
Mesa Laboratories, Inc. (MLAB) was downgraded to C- from C on 11/1/2018 due to a large decline in the total return index, dividend index and valuation index.
C
Hold
4/12/2018Upgraded
Mesa Laboratories, Inc. (MLAB) was upgraded to C from C- on 4/12/2018 due to a noticeable increase in the total return index.
Mesa Laboratories, Inc. (MLAB) was upgraded to C from C- on 4/12/2018 due to a noticeable increase in the total return index.
C
Hold
2/8/2018Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to C- from C+ on 2/8/2018 due to a substantial decline in the growth index, total return index and efficiency index. Earnings per share declined from $0.6 to -$2.932, net income declined 571.14% from $2.35M to -$11.09M, and total capital declined 4.15% from $157.07M to $150.56M.
Mesa Laboratories, Inc. (MLAB) was downgraded to C- from C+ on 2/8/2018 due to a substantial decline in the growth index, total return index and efficiency index. Earnings per share declined from $0.6 to -$2.932, net income declined 571.14% from $2.35M to -$11.09M, and total capital declined 4.15% from $157.07M to $150.56M.
C
Hold
9/28/2017Upgraded
Mesa Laboratories, Inc. (MLAB) was upgraded to C+ from C on 9/28/2017 due to a large increase in the total return index and volatility index.
Mesa Laboratories, Inc. (MLAB) was upgraded to C+ from C on 9/28/2017 due to a large increase in the total return index and volatility index.
C
Hold
9/13/2017Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to C from C+ on 9/13/2017 due to a large decline in the total return index and valuation index.
Mesa Laboratories, Inc. (MLAB) was downgraded to C from C+ on 9/13/2017 due to a large decline in the total return index and valuation index.
C
Hold
8/18/2017Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to C+ from B- on 8/18/2017 due to a substantial decline in the total return index.
Mesa Laboratories, Inc. (MLAB) was downgraded to C+ from B- on 8/18/2017 due to a substantial decline in the total return index.
B
Buy
8/3/2017Upgraded
Mesa Laboratories, Inc. (MLAB) was upgraded to B- from C+ on 8/3/2017 due to a noticeable increase in the growth index, volatility index and solvency index. Operating cash flow increased 173.85% from $979 to $2.68M, and debt to equity declined from 0.56 to 0.5.
Mesa Laboratories, Inc. (MLAB) was upgraded to B- from C+ on 8/3/2017 due to a noticeable increase in the growth index, volatility index and solvency index. Operating cash flow increased 173.85% from $979 to $2.68M, and debt to equity declined from 0.56 to 0.5.
C
Hold
6/8/2017Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to C+ from B on 6/8/2017 due to a significant decline in the growth index, valuation index and efficiency index. Operating cash flow declined 82.01% from $5.44M to $979.
Mesa Laboratories, Inc. (MLAB) was downgraded to C+ from B on 6/8/2017 due to a significant decline in the growth index, valuation index and efficiency index. Operating cash flow declined 82.01% from $5.44M to $979.
B
Buy
4/24/2017Upgraded
Mesa Laboratories, Inc. (MLAB) was upgraded to B from B- on 4/24/2017 due to a noticeable increase in the total return index.
Mesa Laboratories, Inc. (MLAB) was upgraded to B from B- on 4/24/2017 due to a noticeable increase in the total return index.
B
Buy
3/21/2017Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to B- from B on 3/21/2017 due to a noticeable decline in the total return index and valuation index.
Mesa Laboratories, Inc. (MLAB) was downgraded to B- from B on 3/21/2017 due to a noticeable decline in the total return index and valuation index.
B
Buy
2/8/2017Upgraded
Mesa Laboratories, Inc. (MLAB) was upgraded to B from C+ on 2/8/2017 due to a significant increase in the growth index, valuation index and volatility index. Operating cash flow increased 336.3% from -$2.3M to $5.44M, earnings per share increased from $0.62 to $0.84, and EBIT increased 9.24% from $4.23M to $4.62M.
Mesa Laboratories, Inc. (MLAB) was upgraded to B from C+ on 2/8/2017 due to a significant increase in the growth index, valuation index and volatility index. Operating cash flow increased 336.3% from -$2.3M to $5.44M, earnings per share increased from $0.62 to $0.84, and EBIT increased 9.24% from $4.23M to $4.62M.
C
Hold
1/17/2017Downgrade
Mesa Laboratories, Inc. (MLAB) was downgraded to C+ from B- on 1/17/2017 due to a decline in the total return index and volatility index.
Mesa Laboratories, Inc. (MLAB) was downgraded to C+ from B- on 1/17/2017 due to a decline in the total return index and volatility index.
B
Buy
12/16/2016Upgraded
Mesa Laboratories, Inc. (MLAB) was upgraded to B- from C+ on 12/16/2016 due to a large increase in the total return index, volatility index and valuation index.
Mesa Laboratories, Inc. (MLAB) was upgraded to B- from C+ on 12/16/2016 due to a large increase in the total return index, volatility index and valuation index.
C
Hold
11/25/2016Upgraded
Mesa Laboratories, Inc. (MLAB) was upgraded to C+ from C on 11/25/2016 due to a noticeable increase in the total return index, solvency index and volatility index.
Mesa Laboratories, Inc. (MLAB) was upgraded to C+ from C on 11/25/2016 due to a noticeable increase in the total return index, solvency index and volatility index.
C
Hold
11/9/2016Downgrade
Mesa Laboratories Inc. (MLAB) was downgraded to C from C+ on 11/9/2016 due to a major decline in the growth index, efficiency index and total return index. Operating cash flow declined 163.41% from $3.63M to -$2.3M.
Mesa Laboratories Inc. (MLAB) was downgraded to C from C+ on 11/9/2016 due to a major decline in the growth index, efficiency index and total return index. Operating cash flow declined 163.41% from $3.63M to -$2.3M.
C
Hold
11/2/2016Downgrade
Mesa Laboratories Inc. (MLAB) was downgraded to C+ from B- on 11/2/2016 due to a noticeable decline in the total return index, valuation index and volatility index.
Mesa Laboratories Inc. (MLAB) was downgraded to C+ from B- on 11/2/2016 due to a noticeable decline in the total return index, valuation index and volatility index.
B
Buy
10/18/2016Upgraded
Mesa Laboratories Inc. (MLAB) was upgraded to B- from C+ on 10/18/2016 due to a noticeable increase in the total return index and solvency index.
Mesa Laboratories Inc. (MLAB) was upgraded to B- from C+ on 10/18/2016 due to a noticeable increase in the total return index and solvency index.
C
Hold
10/3/2016Downgrade
Mesa Laboratories Inc. (MLAB) was downgraded to C+ from B- on 10/3/2016 due to a decline in the total return index, valuation index and volatility index.
Mesa Laboratories Inc. (MLAB) was downgraded to C+ from B- on 10/3/2016 due to a decline in the total return index, valuation index and volatility index.
B
Buy
9/6/2016Upgraded
Mesa Laboratories Inc. (MLAB) was upgraded to B- from C+ on 9/6/2016 due to an increase in the volatility index.
Mesa Laboratories Inc. (MLAB) was upgraded to B- from C+ on 9/6/2016 due to an increase in the volatility index.
C
Hold
8/11/2016Downgrade
Mesa Laboratories Inc. (MLAB) was downgraded to C+ from B- on 8/11/2016 due to a large decline in the total return index.
Mesa Laboratories Inc. (MLAB) was downgraded to C+ from B- on 8/11/2016 due to a large decline in the total return index.
B
Buy
8/3/2016Downgrade
Mesa Laboratories Inc. (MLAB) was downgraded to B- from B on 8/3/2016 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $1.2648 to $0.51, EBIT declined 55.93% from $5.84M to $2.58M, and operating cash flow declined 47.74% from $6.95M to $3.63M.
Mesa Laboratories Inc. (MLAB) was downgraded to B- from B on 8/3/2016 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $1.2648 to $0.51, EBIT declined 55.93% from $5.84M to $2.58M, and operating cash flow declined 47.74% from $6.95M to $3.63M.
B
Buy
6/9/2016Upgraded
Mesa Laboratories Inc. (MLAB) was upgraded to B from B- on 6/9/2016 due to a substantial increase in the growth index, valuation index and total return index. Operating cash flow increased 601.31% from $991 to $6.95M, earnings per share increased from $0.63 to $1.2648, and EBIT increased 52.48% from $3.83M to $5.84M.
Mesa Laboratories Inc. (MLAB) was upgraded to B from B- on 6/9/2016 due to a substantial increase in the growth index, valuation index and total return index. Operating cash flow increased 601.31% from $991 to $6.95M, earnings per share increased from $0.63 to $1.2648, and EBIT increased 52.48% from $3.83M to $5.84M.
B
Buy
6/2/2016Upgraded
Mesa Laboratories Inc. (MLAB) was upgraded to B- from C+ on 6/2/2016 due to a significant increase in the total return index.
Mesa Laboratories Inc. (MLAB) was upgraded to B- from C+ on 6/2/2016 due to a significant increase in the total return index.
C
Hold
3/11/2016Downgrade
Mesa Laboratories Inc. (MLAB) was downgraded to C+ from B on 3/11/2016 due to a significant decline in the volatility index, total return index and valuation index.
Mesa Laboratories Inc. (MLAB) was downgraded to C+ from B on 3/11/2016 due to a significant decline in the volatility index, total return index and valuation index.
B
Buy
1/22/2016Upgraded
Mesa Laboratories Inc. (MLAB) was upgraded to B from B- on 1/22/2016 due to an increase in the valuation index and dividend index.
Mesa Laboratories Inc. (MLAB) was upgraded to B from B- on 1/22/2016 due to an increase in the valuation index and dividend index.
B
Buy
1/7/2016Downgrade
Mesa Laboratories Inc. (MLAB) was downgraded to B- from B on 1/7/2016 due to a large decline in the total return index.
Mesa Laboratories Inc. (MLAB) was downgraded to B- from B on 1/7/2016 due to a large decline in the total return index.
B
Buy
12/23/2015Upgraded
Mesa Laboratories Inc. (MLAB) was upgraded to B from B- on 12/23/2015 due to an increase in the valuation index and dividend index.
Mesa Laboratories Inc. (MLAB) was upgraded to B from B- on 12/23/2015 due to an increase in the valuation index and dividend index.
B
Buy
11/12/2015Downgrade
Mesa Laboratories Inc. (MLAB) was downgraded to B- from B on 11/12/2015 due to a decline in the total return index.
Mesa Laboratories Inc. (MLAB) was downgraded to B- from B on 11/12/2015 due to a decline in the total return index.
B
Buy
11/6/2015Downgrade
Mesa Laboratories Inc. (MLAB) was downgraded to B from B+ on 11/6/2015 due to a significant decline in the growth index, volatility index and valuation index. Earnings per share declined from $0.63 to $0.47, and EBIT declined 17.46% from $3.64M to $3.01M.
Mesa Laboratories Inc. (MLAB) was downgraded to B from B+ on 11/6/2015 due to a significant decline in the growth index, volatility index and valuation index. Earnings per share declined from $0.63 to $0.47, and EBIT declined 17.46% from $3.64M to $3.01M.
B
Buy
8/31/2015Upgraded
Mesa Laboratories Inc. (MLAB) was upgraded to B+ from B on 8/31/2015 due to an increase in the valuation index and total return index.
Mesa Laboratories Inc. (MLAB) was upgraded to B+ from B on 8/31/2015 due to an increase in the valuation index and total return index.
B
Buy
8/14/2015Downgrade
Mesa Laboratories Inc. (MLAB) was downgraded to B from B+ on 8/14/2015 due to a decline in the valuation index, growth index and efficiency index. Operating cash flow declined 38.34% from $4.64M to $2.86M, EBIT declined 13.31% from $4.2M to $3.64M, and total revenue declined 2.17% from $18.56M to $18.16M.
Mesa Laboratories Inc. (MLAB) was downgraded to B from B+ on 8/14/2015 due to a decline in the valuation index, growth index and efficiency index. Operating cash flow declined 38.34% from $4.64M to $2.86M, EBIT declined 13.31% from $4.2M to $3.64M, and total revenue declined 2.17% from $18.56M to $18.16M.
B
Buy
7/13/2015Upgraded
Mesa Laboratories Inc. (MLAB) was upgraded to B+ from B on 7/13/2015 due to a significant increase in the growth index, volatility index and total return index. Operating cash flow increased 90.79% from $2.43M to $4.64M, EBIT increased 13.3% from $3.71M to $4.2M, and total revenue increased 4.09% from $17.83M to $18.56M.
Mesa Laboratories Inc. (MLAB) was upgraded to B+ from B on 7/13/2015 due to a significant increase in the growth index, volatility index and total return index. Operating cash flow increased 90.79% from $2.43M to $4.64M, EBIT increased 13.3% from $3.71M to $4.2M, and total revenue increased 4.09% from $17.83M to $18.56M.
B
Buy
2/4/2015Downgrade
Mesa Laboratories Inc. (MLAB) was downgraded to B from B+ on 2/4/2015 due to a significant decline in the growth index and efficiency index. Operating cash flow declined 26.7% from $3.32M to $2.43M, EBIT declined 24.33% from $4.9M to $3.71M, and net income declined 21.47% from $3.06M to $2.4M.
Mesa Laboratories Inc. (MLAB) was downgraded to B from B+ on 2/4/2015 due to a significant decline in the growth index and efficiency index. Operating cash flow declined 26.7% from $3.32M to $2.43M, EBIT declined 24.33% from $4.9M to $3.71M, and net income declined 21.47% from $3.06M to $2.4M.
B
Buy
12/26/2014Upgraded
Mesa Laboratories Inc. (MLAB) was upgraded to B+ from B on 12/26/2014 due to a significant increase in the growth index, valuation index and efficiency index. Operating cash flow increased 678.87% from $426 to $3.32M, earnings per share increased from $0.51 to $0.84, and net income increased 62.68% from $1.88M to $3.06M.
Mesa Laboratories Inc. (MLAB) was upgraded to B+ from B on 12/26/2014 due to a significant increase in the growth index, valuation index and efficiency index. Operating cash flow increased 678.87% from $426 to $3.32M, earnings per share increased from $0.51 to $0.84, and net income increased 62.68% from $1.88M to $3.06M.
B
Buy
9/9/2014Downgrade
Mesa Laboratories Inc. (MLAB) was downgraded to B from B+ on 9/9/2014 due to a noticeable decline in the volatility index.
Mesa Laboratories Inc. (MLAB) was downgraded to B from B+ on 9/9/2014 due to a noticeable decline in the volatility index.
B
Buy
8/25/2014Upgraded
Mesa Laboratories Inc. (MLAB) was upgraded to B+ from B on 8/25/2014 due to an increase in the valuation index and dividend index.
Mesa Laboratories Inc. (MLAB) was upgraded to B+ from B on 8/25/2014 due to an increase in the valuation index and dividend index.
B
Buy
8/8/2014Downgrade
Mesa Laboratories Inc. (MLAB) was downgraded to B from B+ on 8/8/2014 due to a large decline in the growth index, volatility index and solvency index. Operating cash flow declined 85.31% from $2.9M to $426, debt to equity increased from 0.26 to 0.42, and earnings per share declined from $0.9485 to $0.51.
Mesa Laboratories Inc. (MLAB) was downgraded to B from B+ on 8/8/2014 due to a large decline in the growth index, volatility index and solvency index. Operating cash flow declined 85.31% from $2.9M to $426, debt to equity increased from 0.26 to 0.42, and earnings per share declined from $0.9485 to $0.51.
B
Buy
5/28/2014Upgraded
Mesa Laboratories Inc. (MLAB) was upgraded to B+ from B on 5/28/2014 due to an increase in the valuation index, volatility index and growth index.
Mesa Laboratories Inc. (MLAB) was upgraded to B+ from B on 5/28/2014 due to an increase in the valuation index, volatility index and growth index.
NASDAQ
03/13/2025 4:00PM Eastern
Quotes delayed
